Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.

Woods JA, Nealy KL, Barrons RW.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):1017-28. doi: 10.1345/aph.1S002. Epub 2013 Jun 4. Review.

PMID:
23737515
2.

Clinical use of aclidinium in patients with COPD.

Reid DJ, Carlson AA.

Int J Chron Obstruct Pulmon Dis. 2014 Apr 28;9:369-79. doi: 10.2147/COPD.S40193. eCollection 2014. Review.

3.

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.

Stone LE, Skelley JW, Kyle JA, Elmore LK.

Am J Health Syst Pharm. 2014 Mar 1;71(5):386-93. doi: 10.2146/ajhp130077. Review.

PMID:
24534593
4.

Aclidinium bromide for stable chronic obstructive pulmonary disease.

Ni H, Soe Z, Moe S.

Cochrane Database Syst Rev. 2014 Sep 19;(9):CD010509. doi: 10.1002/14651858.CD010509.pub2. Review.

PMID:
25234126
5.

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF; AUGMENT COPD study investigators.

Respir Res. 2014 Oct 14;15:123. doi: 10.1186/s12931-014-0123-0.

6.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
7.

Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.

Jones P.

Adv Ther. 2013 Apr;30(4):354-68. doi: 10.1007/s12325-013-0019-2. Epub 2013 Apr 2. Review.

PMID:
23553509
8.

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators.

COPD. 2012 Apr;9(2):90-101. doi: 10.3109/15412555.2012.661492. Epub 2012 Feb 9.

PMID:
22320148
9.

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.

Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, Donohue JF, Bateman ED, Gross NJ, Lamarca R, Caracta C, Gil EG.

Respir Res. 2011 Apr 26;12:55. doi: 10.1186/1465-9921-12-55.

10.

ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.

Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, Caracta CF.

Clin Drug Investig. 2013 Dec;33(12):893-904. doi: 10.1007/s40261-013-0138-1.

PMID:
24085591
11.

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.

Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E.

Respir Med. 2010 Jun;104(6):865-72. doi: 10.1016/j.rmed.2009.12.003. Epub 2009 Dec 30.

12.

The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.

Maltais F, Milot J.

Ther Adv Respir Dis. 2012 Dec;6(6):345-61. doi: 10.1177/1753465812463626. Epub 2012 Oct 17. Review.

PMID:
23075544
13.

Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.

Lee SH, Lee J, Yoo KH, Uh ST, Park MJ, Lee SY, Kim JY, Kim DK, Kim SJ, Lee KH, Yoo CG.

Respirology. 2015 Nov;20(8):1222-8. doi: 10.1111/resp.12641. Epub 2015 Sep 15.

14.

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E.

Chest. 2012 Mar;141(3):745-752. doi: 10.1378/chest.11-0406. Epub 2011 Sep 8.

PMID:
21903737
15.

Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.

Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C; LAS-MD-35 study investigators.

Respir Med. 2013 Dec;107(12):1957-65. doi: 10.1016/j.rmed.2013.07.001. Epub 2013 Jul 31.

16.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E.

Eur Respir J. 2012 Oct;40(4):830-6. Epub 2012 Mar 22.

17.

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.

Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, Jarreta D, Garcia Gil E.

Pulm Pharmacol Ther. 2012 Jun;25(3):248-53. doi: 10.1016/j.pupt.2012.03.008. Epub 2012 Apr 4. Erratum in: Pulm Pharmacol Ther. 2013 Apr;26(2):305.

PMID:
22497752
18.

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.

Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG.

COPD. 2010 Oct;7(5):331-6. doi: 10.3109/15412555.2010.510158.

PMID:
20854047
19.

Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.

Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, Gil EG.

COPD. 2013 Aug;10(4):511-22. doi: 10.3109/15412555.2013.814626. Epub 2013 Jul 2.

20.

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.

Cazzola M, Page CP, Matera MG.

Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. Review.

PMID:
23566013

Supplemental Content

Support Center